The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of lymph node characteristics on clinical outcomes in clinical N2 non-small cell lung cancer patients treated with chemoradiotherapy: Single- vs. multiple-stations, bulky vs. non-bulky and discrete vs. infiltrative.
 
Yuki Kato
No Relationships to Disclose
 
Hibiki Udagawa
Honoraria - AstraZeneca Japan; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; MSD; Novartis; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); MSD K.K. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Atsuyuki Nakanishi
No Relationships to Disclose
 
Keiju Aokage
Honoraria - AstraZeneca; Care Net; Chugai Pharma; Covidien; CSL Behring; Daiichi Sankyo/UCB Japan; Fukuyama city hospital; Guardant Health; International Life Sciences Institute; Japan Blood Products Organization; Johnson & Johnson; KANEHARA & Co., LTD; Kyowa Kirin International; Lilly Japan; M3; Mediacal view; Medical market vision; medical tribune; MSD K.K; nankodou; Phase one; Taiho Pharmaceutical; Zaiosoft
Consulting or Advisory Role - AstraZeneca; Olympus Medical Systems; Sano hospital; Taiho Pharmaceutical
Research Funding - AstraZeneca; MSD
 
Masaki Nakamura
Honoraria - AstraZeneca; Illumina
Research Funding - Illumina
 
Hidehiro Hojo
No Relationships to Disclose
 
Yu Tanaka
No Relationships to Disclose
 
Tetsuya Sakai
Honoraria - Amco; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; MSD; Novartis; Olympus; Taiho Pharmaceutical
Research Funding - Amgen; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Merck
 
Hiroki Izumi
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Eri Sugiyama
No Relationships to Disclose
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst)
 
Shigeki Umemura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Takeda
Research Funding - Daiichi sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Lilly; Merck; Novartis
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi sankyo; Kyowa Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; RIKEN GENESIS CO., LTD.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; Bayer HealthCare Pharmaceuticals Inc.,; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Novartis; Pharma Mar, S.A.; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)